JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Nogami, Akihiko; Kurita, Takashi; Kusano, Kengo; Goya, Masahiko; Shoda, Morio; Tada, Hiroshi; Naito, Shigeto; Yamane, Teiichi; Kimura, Masaomi; Shiga, Tsuyoshi; Soejima, Kyoko; Noda, Takashi; Yamasaki, Hiro; Aizawa, Yoshifusa; Ohe, Tohru; Kimura, Takeshi; Kohsaka, Shun; Mitamura, Hideo

doi:10.1002/joa3.12649

Cited by 27 publications

(38 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current guideline recommends the continuation of oral anticoagulants in patients with CHADS2 scores equal to or above 2, considering the potential AF recurrence following the procedures. 22 However, we cannot predict AF recurrence by using these scorings. 23 U‐IXP might be a useful index to distinguish optimal candidates for long‐term anticoagulation therapy following the procedures.…”

Section: Discussionmentioning

confidence: 96%

Urinary isoxanthopterin as a novel predictor following catheter ablation for atrial fibrillation

Koi

Kataoka

Uchida

et al. 2023

Journal of Arrhythmia

View full text Add to dashboard Cite

Pulmonary vein isolation for atrial fibrillation (AF) has become widely accepted as a therapeutic strategy irrespective of the AF duration. However, the success rates of the first procedure are limited to around 50%-70% in paroxysmal and 40%-50% in persistent AF. 1 Of note, asymptomatic recurrence rate is approximately 50% following catheter ablation. 2,3 Patients with asymptomatic recurrence are at risk of cardiovascular events due to its delayed recognition and physicians' intervention. 4 Implantable loop recorders are recommended to monitor the recurrence of AF following catheter ablation. 5 However, given its invasiveness and high cost, it cannot be recommended for all Japanese candidates for catheter ablation. 6 Thus, methodologies to identify high-risk cohorts have been desired.Several biomarkers, including myocardial injury biomarkers, natriuretic peptides, and serum uric acid, as well as left atrial size, are

show abstract

Section: Discussionmentioning

confidence: 96%

Urinary isoxanthopterin as a novel predictor following catheter ablation for atrial fibrillation

Koi

Kataoka

Uchida

et al. 2023

Journal of Arrhythmia

View full text Add to dashboard Cite

show abstract

“…The present study excluded patients with a baseline left ventricular ejection fraction (LVEF) <40%. All patients undergoing pacemaker implantation were selected according to recent guidelines (Nogami et al, 2021 , 2022 ). Forty‐one patients (13 with HBP, 14 with RVP, and 14 controls) were included.…”

Section: Methodsmentioning

confidence: 99%

“…All patients undergoing pacemaker implantation were selected according to recent guidelines (Nogami et al, 2021(Nogami et al, , 2022. Forty-one patients (13 with HBP, 14 with RVP, and 14 controls) were included.…”

Section: Study Populationmentioning

confidence: 99%

Depolarization and repolarization dynamics after His‐bundle pacing: Comparison with right ventricular pacing and native ventricular conduction

Inden

Watanabe

Tsurumi

et al. 2022

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

“…Implantable cardioverter defibrillators (ICDs) are a well-established treatment for preventing sudden cardiac death. 1,2 Ventricular tachyarrhythmias detection is an essential function of ICDs. However, undersensing may be caused by poor lead fixation, lead fracture, or progressive myocardial disease.…”

Section: Introductionmentioning

confidence: 99%

“…Implantable cardioverter defibrillators (ICDs) are a well‐established treatment for preventing sudden cardiac death 1,2 . Ventricular tachyarrhythmias detection is an essential function of ICDs.…”

Section: Introductionmentioning

confidence: 99%

Lead switching to resolve undersensing of ventricular tachycardia by a cardiac resynchronization therapy defibrillator

Kataoka

Daigo

Yazaki

et al. 2022

Pacing Clinical Electrophis

View full text Add to dashboard Cite

A 63‐year‐old man was admitted to the hospital due to ventricular tachycardia (VT) undersensing, caused by decreased R‐wave amplitude in a cardiac resynchronization therapy defibrillator. The R‐wave amplitude of VT sensed by the left ventricular (LV) lead was markedly higher than that by the right ventricular (RV) lead; therefore, we reconnected the IS‐1 RV lead to the LV IS‐1 port and the IS‐1 LV lead to the RV IS‐1 port to resolve this issue. After discharge, it was confirmed that VT was successfully terminated by the second sequence of intrinsic ATP (iATP, Medtronic, Minneapolis, MN, USA) from the LV lead.

show abstract

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Cited by 27 publications

References 189 publications

Urinary isoxanthopterin as a novel predictor following catheter ablation for atrial fibrillation

Urinary isoxanthopterin as a novel predictor following catheter ablation for atrial fibrillation

Depolarization and repolarization dynamics after His‐bundle pacing: Comparison with right ventricular pacing and native ventricular conduction

Lead switching to resolve undersensing of ventricular tachycardia by a cardiac resynchronization therapy defibrillator

Contact Info

Product

Resources

About